Know Cancer

or
forgot password

Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab


Phase 4
N/A
N/A
Not Enrolling
Both
Carcinoma

Thank you

Trial Information

Evaluation of Corrected QT Interval From Clinical Studies Conducted With Bevacizumab


Inclusion Criteria:



- Signed Informed Consent Form

- Enrollment in one of a list of certain randomized, controlled bevacizumab trials

Exclusion Criteria:

- Implantable pacemaker or automatic implantable cardioverter defibrillator (AICD)

- Congenital long QT syndrome

- Family history of long QT syndrome

- Clinically significant bradycardia (defined as < 50 beats/minute)

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Principal Investigator

Jane Huang, M.D.

Investigator Role:

Study Director

Investigator Affiliation:

Genentech

Authority:

United States: Food and Drug Administration

Study ID:

AVF4223g

NCT ID:

NCT00477425

Start Date:

June 2007

Completion Date:

Related Keywords:

  • Carcinoma
  • Avastin
  • Carcinoma

Name

Location